Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAF(V600E) melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Zhang, Gao, Frederick, Dennie T., Wu, Lawrence, Wei, Zhi, Krepler, Clemens, Srinivasan, Satish, Chae, Young Chan, Xu, Xiaowei, Choi, Harry, Dimwamwa, Elaida, Ope, Omotayo, Shannan, Batool, Basu, Devraj, Zhang, Dongmei, Guha, Manti, Xiao, Min, Randell, Sergio, Sproesser, Katrin, Xu, Wei, Liu, Jephrey, Karakousis, Giorgos C., Schuchter, Lynn M., Gangadhar, Tara C., Amaravadi, Ravi K., Gu, Mengnan, Xu, Caiyue, Ghosh, Abheek, Xu, Weiting, Tian, Tian, Zhang, Jie, Zha, Shijie, Liu, Qin, Brafford, Patricia, Weeraratna, Ashani, Davies, Michael A., Wargo, Jennifer A., Avadhani, Narayan G., Lu, Yiling, Mills, Gordon B., Altieri, Dario C., Flaherty, Keith T., Herlyn, Meenhard
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4855947/
https://ncbi.nlm.nih.gov/pubmed/27043285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI82661
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars